SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma gets EIR from USFDA for manufacturing facility at Paithan

02 Jul 2026 Evaluate

Ajanta Pharma has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its manufacturing facility at Paithan, Maharashtra. The inspection has been classified as Voluntary Action Indicated (VAI).

The current Good Manufacturing Practices (cGMP) inspection of the Paithan facility was conducted by the USFDA from April 13, 2026 to April 21, 2026. 

Ajanta Pharma is a specialty pharmaceutical formulation company having major focus on branded generic business across India, Asia & Africa. 


Ajanta Pharma Share Price

3325.00 -18.80 (-0.56%)
03-Jul-2026 15:14 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1905.45
Dr. Reddys Labs. 1374.05
Cipla 1458.20
Zydus Lifesciences 1139.55
Lupin 2477.85
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: